1007 related articles for article (PubMed ID: 21622720)
1. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
3. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
4. SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.
Zhang QY; Tao SY; Lu C; Li JJ; Li XM; Yao J; Jiang Q; Yan B
Mol Med Rep; 2020 Jun; 21(6):2571-2579. PubMed ID: 32323773
[TBL] [Abstract][Full Text] [Related]
5. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
6. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
8. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
[TBL] [Abstract][Full Text] [Related]
9. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
10. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
11. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
Saraswati S; Kumar S; Alhaider AA
Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
[TBL] [Abstract][Full Text] [Related]
12. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
Shen G; Li Y; Du T; Shi G; Dai L; Chen X; Zheng R; Li W; Su X; Zhang S; Wei Y; Yang S; Deng H
Neoplasma; 2012; 59(5):486-93. PubMed ID: 22668017
[TBL] [Abstract][Full Text] [Related]
13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
14. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
15. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
16. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling.
Guan YY; Liu HJ; Luan X; Xu JR; Lu Q; Liu YR; Gao YG; Zhao M; Chen HZ; Fang C
Phytomedicine; 2015 Jan; 22(1):103-10. PubMed ID: 25636878
[TBL] [Abstract][Full Text] [Related]
17. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Nicoli S; Ribatti D; Cotelli F; Presta M
Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
[TBL] [Abstract][Full Text] [Related]
18. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
[TBL] [Abstract][Full Text] [Related]
20. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
